一分钟看懂
这是一项关于肾细胞癌的II 期研究，登记的药物或干预包括Stereotactic Body Radiation Therapy (SBRT)；Anlotinib；Bemarituzumab，当前状态为尚未开始招募。登记地点显示中国福州有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Stereotactic Body Radiation Therapy (SBRT)；Anlotinib；Bemarituzumab · II 期
登记条件中文摘要
年龄范围：18岁至80岁
登记的基本范围为不限性别，年龄18岁至80岁；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Fujian Cancer Hospital · 福州
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- 1. Aged 18 to 80 years, regardless of sex.
- 2. Histologically or cytologically confirmed locally advanced/metastatic renal cell carcinoma (RCC) inoperable/refused for surgery, or post-operative locally recurrent/metastatic RCC; pathological types include clear cell carcinoma and papillary renal cell carcinoma.
- 3. ECOG performance status 0 or 1.
- 4. At least 50% of all evaluable metastatic lesions are eligible for stereotactic body radiation therapy (SBRT).
- 5. No contraindications to radiotherapy, targeted therapy or immunotherapy.
- 6. At least one radiologically measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
- 7. Capable and willing to comply with the study protocol including scheduled visits, treatment plan, laboratory tests and other study-related procedures during the study period.
- 8. Signed written informed consent form.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07470840；登记信息更新于 2026-10-01；本站同步于 2026-10-08。